ClinicalTrials.gg
CompletedNCT03181763Updated Mar 4, 2025

Evaluation of MDMA on Startle Response

A Phase 1 interventional study of Placebo and Midomafetamine in Startle Response, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-04.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2020, 6 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants.

The main question it aims to answer is: Does MDMA impact participant's performance on a startle test?

Researchers will compare healthy volunteers who have taken MDMA to those who have taken placebo.

Participants will first undergo a 1-hour startle test. The next day, they will be randomized to receive either MDMA or placebo followed by another startle test and vitals signs and blood measurements. Participants will return the next day for a final startle test. Their sleep will be tracked by a Fitbit device.

Read the detailed description

This is a randomized, blinded, placebo-controlled Phase 1 study that aims to evaluate the impact of 3,4-methylenedioxymethamphetamine (MDMA) on startle response.

This study will enroll healthy participants. At Visit 1, all participants will undergo a 1-hour startle test. Acoustic startle will be measured through assessing eye-blink response from the orbicularis oculi muscles in response to a 106 dB noise, using sensors under the eye. While watching the computer monitor, the participant will also experience several brief blasts of air directed at the throat.

At Visit 2 (24 hours later), participants will be randomized to receive 100 mg of MDMA or inactive placebo, after which they will undergo another startle test. Participants enrolled in the study who agree to do this will have their blood drawn to measure levels of oxytocin, and possibly other hormones or proteins, such as cortisol or brain-derived neurotrophic factor (BDNF). Measuring oxytocin will be blind to condition, and the decision will happen before randomization to either condition. Blood will be drawn before MDMA or placebo administration, and eight times afterwards.The researchers will measure pulse, blood pressure and temperature once before and six times after receiving MDMA or placebo, and study participants will complete a questionnaire about their experience.

At Visit 3, participants will return for a final startle test and recall task. Sleep will be measured via self-report and Fitbit during study participation.

02

Conditions studied

  • Startle Response

Keywords

  • MDMA
  • Startle response
  • sleep
  • Oxytocin
03

In context

Lead sponsor

Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persons aged 21 to 55.
  • Ability to visually read and understand English language.
  • Live within in metro Atlanta area
  • Previously used MDMA in a recreational or research setting
  • If a person is of (able to bear children), they must have a negative pregnancy test at study entry and prior to the Experimental Session. They must agree to use adequate through 10 days after the last dose of MDMA. Adequate birth control methods include intrauterine device (IUD), injected or implanted hormonal methods, abstinence, oral hormones plus a barrier contraception or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e. condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom). Not of childbearing potential is defined as permanent sterilization, , or male.
  • (For sub-study measuring serum oxytocin) Willing to have periodic blood draws

Exclusion criteria

Exclusion Criteria:

  • Upon review of medical or psychiatric history, have any current or past diagnosis that would be considered a risk to participating in the study.
  • Are abusing illegal drugs.
  • Current use of any psychoactive medications, including antidepressants, mood stabilizers, sedatives, stimulants, antipsychotics, anxiolytics, or beta-blockers
  • Are not able to give adequate .
  • Uncontrolled hypertension, or cardiac arrhythmia, as detected by .
  • Currently pregnant or breast-feeding.
  • History of acute angle glaucoma.
  • Hearing impairment as assessed by audiometer; unable to detect tones below 40 dB in right or left ear.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    100 mg MDMA HCl

    Participants receive 100 mg MDMA HCl on their second visit

    Drug: Midomafetamine · Behavioral: Acoustic startle

  • Placebo comparator
    Placebo

    Participants receive inactive placebo on their second visit

    Drug: Placebo · Behavioral: Acoustic startle

Interventions

  • DrugPlacebo

    Participants will receive inactive placebo on their second visit.

    Also known as: inactive placebo, lactose

  • Participants will receive 100 mg midomafetamine HCl on their second visit

    Also known as: 3,4-methylenedioxymethamphetamine, MDMA, midomafetamine HCl

  • BehavioralAcoustic startle

    Startle assessment

    Also known as: startle test

06

What researchers measure

Primary outcomes

  1. EMG of right orbicularis oculi muscle

    Description: Measure of startle response to noise after fear extinction training

    Time frame: Four days post-enrollment

Secondary outcomes

  1. Systolic blood pressure pre-drug

    Systolic blood pressure measured prior to administration of MDMA or placebo

    Time frame: 5 minutes pre-drug

  2. Systolic blood pressure 45 min post-drug

    Systolic blood pressure measured 45 minutes after MDMA or placebo administration

    Time frame: 45 minutes post-drug

  3. Systolic blood pressure 1 h 15 min post-drug

    Systolic blood pressure measured 1 hour 15 minutes after MDMA or placebo administration

    Time frame: 1 hour 15 minutes post drug

  4. Systolic blood pressure 1 h 45 min post-drug

    Systolic blood pressure measured 1 hour 45 minutes after MDMA or placebo administration

    Time frame: 1 hour 45 minutes post drug

  5. Systolic blood pressure 3 h post-drug

    Systolic blood pressure measured 3 hours after MDMA or placebo administration

    Time frame: 3 hours post-drug

  6. Systolic blood pressure 4 h post-drug

    Systolic blood pressure measured 4 hours after MDMA or placebo administration

    Time frame: 4 hours post-drug

  7. Systolic blood pressure 5 h post-drug

    Systolic blood pressure measured 5 hours after MDMA or placebo administration

    Time frame: 5 hours post-drug

  8. Systolic blood pressure 6 h post-drug

    Systolic blood pressure measured 6 hours after MDMA or placebo administration

    Time frame: 6 hours post-drug

  9. Diastolic blood pressure pre-drug

    Diastolic blood pressure measured prior to MDMA or placebo administration

    Time frame: 5 minutes pre-drug

  10. Diastolic blood pressure 45 min post-drug

    Diastolic blood pressure measured 45 minutes after MDMA or placebo administration

    Time frame: 45 minutes post-drug

  11. Diastolic blood pressure 1 h 15 min post-drug

    Diastolic blood pressure measured 1 h 15 minutes after MDMA or placebo administration

    Time frame: 1 hour 15 minutes post-drug

  12. Diastolic blood pressure 1 h 45 min post-drug

    Diastolic blood pressure measured 1 h 45 minutes after MDMA or placebo administration

    Time frame: 1 hour 45 minutes post drug

  13. Diastolic blood pressure 3 h post-drug

    Diastolic blood pressure measured 3 hours after MDMA or placebo administration

    Time frame: 3 hours post-drug

  14. Diastolic blood pressure 4 hours post-drug

    Diastolic blood pressure measured 4 hours after MDMA or placebo administration

    Time frame: 4 hours post-drug

  15. Diastolic blood pressure 5 hours post-drug

    Diastolic blood pressure measured 5 hours after MDMA or placebo administration

    Time frame: 5 hours post-drug

  16. Diastolic blood pressure 6 hours post-drug

    Diastolic blood pressure measured 6 hours after MDMA or placebo administration

    Time frame: 6 hours post-drug

  17. Pulse pre-drug

    Pulse (assessing heart rate) measured prior to MDMA or placebo administration

    Time frame: 5 minutes pre-drug

  18. Pulse 45 min post-drug

    Pulse (assessing heart rate) measured 45 min after MDMA or placebo administration

    Time frame: 45 minutes post-drug

  19. Pulse 1 h 15 min post-drug

    Pulse (assessing heart rate) measured 1 hour 15 min after MDMA or placebo administration

    Time frame: 1 hour 15 minutes post-drug

  20. Pulse 1 h 45 min post-drug

    Pulse (assessing heart rate) measured 1 hour 45 min after MDMA or placebo administration

    Time frame: 1 hour 45 minutes post-drug

  21. Pulse 3 h post-drug

    Pulse (assessing heart rate) measured 3 hours after MDMA or placebo administration

    Time frame: 3 hours post-drug

  22. Pulse 4 h post-drug

    Pulse (assessing heart rate) measured 4 hours after MDMA or placebo administration

    Time frame: 4 hours post-drug

  23. Pulse 5 h post-drug

    Pulse (assessing heart rate) measured 5 hours after MDMA or placebo administration

    Time frame: 5 hours post-drug

  24. Pulse 6 h post-drug

    Pulse (assessing heart rate) measured 6 hours after MDMA or placebo administration

    Time frame: 6 hours post-drug

  25. Body temperature pre-drug

    Body temperature measured before MDMA or placebo administration

    Time frame: 5 minutes pre-drug

  26. Body temperature 45 minutes post-drug

    Body temperature measured 45 minutes after MDMA or placebo administration

    Time frame: 45 minutes post-drug

  27. Body temperature 1 h 15 minutes post-drug

    Body temperature measured 1 hour 15 minutes after MDMA or placebo administration

    Time frame: 1 hour 15 minutes post-drug

  28. Body temperature 1 h 45 minutes post-drug

    Body temperature measured 1 hour 45 minutes after MDMA or placebo administration

    Time frame: 1 hour 45 minutes post-drug

  29. Body temperature 3 hours post-drug

    Body temperature measured 3 hours after MDMA or placebo administration

    Time frame: 3 hours post-drug

  30. Body temperature 4 hours post-drug

    Body temperature measured 4 hours after MDMA or placebo administration

    Time frame: 4 hours post-drug

  31. Body temperature 5 hours post-drug

    Body temperature measured 5 hours after MDMA or placebo administration

    Time frame: 5 hours post-drug

  32. Body temperature 6 hours post-drug

    Body temperature measured 6 hours after MDMA or placebo administration

    Time frame: 6 hours post-drug

  33. Plasma oxytocin (OT) levels predrug

    In people who agree to it, blood collected to assess levels of oxytocin prior to MDMA or placebo administration on day of drug administration

    Time frame: 5 min prior to drug administration

  34. Plasma oxytocin (OT) levels 5 min post-drug

    In people who agree to it, blood collected to assess levels of oxytocin approximately 5 minutes after MDMA or placebo administration

    Time frame: 5 min post-drug administration

  35. Plasma oxytocin (OT) levels 20 min post-drug

    In people who agree to it, blood collected to assess levels of oxytocin approximately 20 minutes after MDMA or placebo administration

    Time frame: 20 min post-drug administration

  36. Plasma oxytocin (OT) levels 95 min post-drug

    In people who agree to it, blood collected to assess levels of oxytocin approximately 95 minutes (approximately 1.5 h) after MDMA or placebo administration

    Time frame: 95 min post-drug administration

  37. Plasma oxytocin (OT) levels 110 min post-drug

    In people who agree to it, blood collected to assess levels of oxytocin approximately 110 minutes after MDMA or placebo administration

    Time frame: 110 min post-drug administration

  38. Plasma oxytocin (OT) levels 185 min post-drug

    In people who agree to it, blood collected to assess levels of oxytocin approximately 185 minutes after MDMA or placebo administration

    Time frame: 185 min post-drug administration

  39. Plasma oxytocin (OT) levels 200 min post-drug

    In people who agree to it, blood collected to assess levels of oxytocin approximately 200 minutes after MDMA or placebo administration

    Time frame: 200 min post-drug administration

  40. Plasma oxytocin (OT) levels 240 min post-drug

    In people who agree to it, blood collected to assess levels of oxytocin approximately 240 minutes after MDMA or placebo administration

    Time frame: 240 min post-drug administration

  41. Plasma oxytocin (OT) levels 300 min post-drug

    In people who agree to it, blood collected to assess levels of oxytocin approximately 300 minutes after MDMA or placebo administration

    Time frame: 300 min post-drug administration

07

Study locations

1 site
  • Emory University
    Atlanta, Georgia 30329, United States
08

References and documents

Publications

  • Maples-Keller JL, Norrholm SD, Burton M, Reiff C, Coghlan C, Jovanovic T, Yasinski C, Jarboe K, Rakofsky J, Rauch S, Dunlop BW, Rothbaum BO. A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol. 2022 Mar;36(3):368-377. doi: 10.1177/02698811211069124. Epub 2022 Feb 15. PubMed 35166140 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Aug 2020, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2017
First posted
Jun 9, 2017
StartActual
Mar 14, 2017
Primary completionActual
Aug 1, 2020
CompletionActual
Aug 1, 2020
Last update
Mar 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03181763
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Jun 9, 2017
Start date
Mar 14, 2017
Primary completion
Aug 1, 2020
Completion
Aug 1, 2020
Last update
Mar 4, 2025

Study contacts

Barbara Rothbaum
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion